339 related articles for article (PubMed ID: 29882235)
21. Oxygen Self-Sufficient Core-Shell Metal-Organic Framework-Based Smart Nanoplatform for Enhanced Synergistic Chemotherapy and Photodynamic Therapy.
Ren SZ; Wang B; Zhu XH; Zhu D; Liu M; Li SK; Yang YS; Wang ZC; Zhu HL
ACS Appl Mater Interfaces; 2020 Jun; 12(22):24662-24674. PubMed ID: 32394704
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
[TBL] [Abstract][Full Text] [Related]
23. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
24. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
[TBL] [Abstract][Full Text] [Related]
25. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W
J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973
[TBL] [Abstract][Full Text] [Related]
27. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
28. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
[TBL] [Abstract][Full Text] [Related]
29. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
30. Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma.
Hou G; Qian J; Guo M; Xu W; Wang J; Wang Y; Suo A
J Colloid Interface Sci; 2022 Dec; 628(Pt B):968-983. PubMed ID: 36037718
[TBL] [Abstract][Full Text] [Related]
31. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.
Sasikumar PG; Ramachandra RK; Adurthi S; Dhudashiya AA; Vadlamani S; Vemula K; Vunnum S; Satyam LK; Samiulla DS; Subbarao K; Nair R; Shrimali R; Gowda N; Ramachandra M
Mol Cancer Ther; 2019 Jun; 18(6):1081-1091. PubMed ID: 31015307
[TBL] [Abstract][Full Text] [Related]
32. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
33. A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy.
Li M; Zhao D; Yan J; Fu X; Li F; Liu G; Fan Y; Liang Y; Zhang X
ACS Nano; 2024 May; 18(20):12870-12884. PubMed ID: 38727063
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
[TBL] [Abstract][Full Text] [Related]
35. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
36. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.
He C; Duan X; Guo N; Chan C; Poon C; Weichselbaum RR; Lin W
Nat Commun; 2016 Aug; 7():12499. PubMed ID: 27530650
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Zhu X; Lang J
J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
39. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt J; Avigan D
Blood; 2017 Jan; 129(3):275-279. PubMed ID: 27919908
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
